Synonym
Nivasorexant; ACT-539313; ACT 539313; ACT539313;
IUPAC/Chemical Name
(R)-(3-(3-(2H-1,2,3-triazol-2-yl)benzyl)morpholino)(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
InChi Key
GKPHAIOJCHBZCT-HXUWFJFHSA-N
InChi Code
InChI=1S/C23H23N7O2/c1-17-5-6-21(22(13-17)30-26-9-10-27-30)23(31)28-11-12-32-16-20(28)15-18-3-2-4-19(14-18)29-24-7-8-25-29/h2-10,13-14,20H,11-12,15-16H2,1H3/t20-/m1/s1
SMILES Code
O=C(C1=C(N2N=CC=N2)C=C(C)C=C1)N3CCOC[C@H]3CC4=CC(N5N=CC=N5)=CC=C4
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
The orexin system consists of two neuropeptides (orexins A and B) and two receptors (OX1 and OX2). Selective OX1 receptor antagonists (SO1RA) are gaining interest for their potential use in the treatment of CNS disorders, including substance abuse, eating, obsessive compulsive, or anxiety disorders. While blocking OX2 reduces wakefulness, the expected advantage of selectively antagonizing OX1 is the ability to achieve clinical efficacy without the promotion of sleep.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
429.48
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Williams JT, Bolli MH, Brotschi C, Sifferlen T, Steiner MA, Treiber A, Gatfield J, Boss C. Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials. J Med Chem. 2024 Feb 8. doi: 10.1021/acs.jmedchem.3c01894. Epub ahead of print. PMID: 38331429.
2: Bergamini G, Durkin S, Steiner MA. Selective orexin 1 receptor antagonism does not affect effort-based responding for sucrose reward in rats. J Psychopharmacol. 2024 Feb 7:2698811241229523. doi: 10.1177/02698811241229523. Epub ahead of print. PMID: 38327032.
3: McElroy SL, Coloma PM, Berger B, Guerdjikova AI, Joyce JM, Liebowitz MR, Pain S, Rabasa C. Efficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder: A randomized, Phase II proof of concept trial. Int J Eat Disord. 2023 Nov;56(11):2120-2130. doi: 10.1002/eat.24039. Epub 2023 Aug 16. PMID: 37584285.
4: Berger B, Kaufmann P, Berse M, Treiber A, Grignaschi N, Dingemanse J. Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects. Pharmacol Res Perspect. 2023 Oct;11(5):e01143. doi: 10.1002/prp2.1143. PMID: 37800597; PMCID: PMC10557102.
